Inherited biallelic mutations of the ATM (ataxia-telangiectasia mutated) gene cause ataxia-telangiectasia, a rare autosomal recessive disorder associated with a high incidence of childhood leukaemias and lymphomas, suggesting that ATM gene alterations may be involved in lymphomagenesis. Loss of heterozygosity at 11q22-23 (location of the ATM gene) is a frequent event in sporadic lymphoid tumours, and several studies have reported a high prevalence of ATM gene alterations in diverse sporadic lymphoproliferative disorders, adding evidence to the postulated contribution of ATM in the pathogenesis of these tumours. This mini-review will summarize the recently published data concerning the ATM gene in sporadic lymphoid malignancies and will discuss the apparent paradox between the predominance of nonsense mutations observed in patient with ataxia-telangiectasia and the high proportion of missense alterations found in sporadic lymphoid tumours.
Introduction
ATM (ataxia-telangiectasia mutated) germline mutations are responsible for ataxia-telangiectasia (A-T), a rare autosomal recessive disorder characterized by progressive cerebellar ataxia, bulbar telangiectasia, high sensitivity to ionizing radiation, humoral and cellular immunodeficiencies, premature aging, endocrine abnormalities and cancer susceptibility. While 30-40% of all A-T patients will develop neoplasia during their life, 1 10-15% of them will present a lymphoid malignancy in childhood or early adulthood. 2 The ATM gene is located at the 11q22-23 bands and encodes a nuclear 370-kDa phosphoprotein known to associate with chromosomal regions containing double-strand breaks. ATM amino-acid sequence contains leucine zipper, helix-turn-helix and phosphatidylinositol-3 kinase (PI-3K) motifs, which share homology with diverse protein kinases involved in checkpoint/damage responses, such as Tel1p, ATR, Rad3, Mec1p, MEI-41 and DNA-PKcs. Biochemical studies have identified various substrates for the ATM protein: targets for ATM catalytic activity include the nuclear tyrosine kinase c-Abl, the replication protein A, p53, Chk2, Nbs1, BRCA1, FANCD2 and SMC1. On the whole, these observations place ATM as an upstream mediator of a kinase cascade that links the detection of DNA damage to cell-cycle progression, genetic recombination and apoptosis (reviewed by Khanna et al 3 and Shiloh 4 ).
Most A-T patients are compound heterozygotes. About 71-86% of the mutations result in premature protein truncation, while 14-29% are missense mutations or short in-frame deletions or insertions. [5] [6] [7] [8] Differences in screening methodologies and targeted populations may account for these variations. At a cellular level, the A-T phenotype is characterized by features of genetic instability and abnormal sensitivity to ionizing radiations and radiomimetics, altered DNA repair and disruptions of cell-cycle checkpoints. Furthermore, genetically deficient atm mice (atm À/À mice) display a similar phenotype to A-T patients in vivo and in vitro, with neurological abnormalities, immune deficiency, radiosensitivity and high incidence of lymphoproliferative disorders, in particular thymic lymphomas. 9 ATM heterozygous alterations are postulated to predispose to malignancies. Indeed, older epidemiological studies suggest that obligate carriers in A-T families are at higher risk of developing epithelial neoplasia, in particular breast cancer (BC). 10 Although molecular studies have first failed to demonstrate the presence of constitutional truncating mutations in sporadic premenopausal BC patients, 11 more recent works have consistantly identified ATM germline missense mutations in a fraction of early BC patients with or with no family history. [12] [13] [14] Furthermore, a recent study has provided indirect evidence that ATM polymorphism may modulate the penetrance of other cancer-predisposing genes such as MLH1 and MSH2. 15 This review will enumerate and discuss current evidence supporting the contention that ATM alterations may also predispose and contribute to the development of lymphoid neoplasias.
Adult lymphoid leukaemias
T-cell prolymphocytic leukaemia (T-PLL) is an aggressive lymphoid malignancy affecting predominantly adults while it arises at a younger age in A-T patients. Earlier investigations have shown that 40-46% of analysed T-PLL exhibit alterations of both ATM alleles. These studies have documented loss of heterozygosity (LOH) encompassing the ATM locus associated to mutations in the remaining allele suggesting that, in sporadic T-PLL, the ATM gene could operate as a classical tumour suppressor gene. Of note, the observed ATM mutations were primarly missense mutations, clustered in the PI-3K domain. 16, 17 Additional analyses indicate that these genetic lesions are mostly acquired. 18 As published by Haidar et al, 19 LOH in a region that encompasses the ATM gene locus is frequently observed in adult acute lymphoblastic leukaemia (ALL) and appears to confer a favourable prognosis. Gronback et al 20 studied 120 cases of lymphoid malignancies in which 27 were adult Bprecursor ALL. In this series, a single mutation (4%) with a putative pathogenic effect and three probably silent variants were found, suggesting a rather low frequency of ATM mutations in adult B-precursor ALL.
Adult lymphomas
Initial investigations have detected only a minority of ATM missense mutations in B-cell non-Hodgkin's lymphomas (B-NHL) or B-NHL cell lines tested (3/37). 16 However, acquired deletion of 11q was highly significantly associated with shorter survival, suggesting that, as in B-CLL, ATM inactivation could be an important determinant of the outcome. 21 Follicular centre cell lymphoma (FCL) is the most prevalent low-grade B-NHL in Western societies and is characterized by a relatively indolent clinical course and long median survival. However, hemizygous deletions of ATM gene have been described in a minority of FCL (11%) 21 as well as point mutations (8%). 20 B-cell chronic lymphocytic leukaemia (B-CLL) is a common neoplasia, which consists of proliferating malignant lymphocytes that are frequently harbouring deletion of 11q. In all, 26-40% of sporadic B-CLL exhibit alterations in ATM gene structure and/or expression. [22] [23] [24] [25] [26] In contrast to T-PLL, ATM alterations in B-CLL cases fail to follow the postulated pathway of tumour suppressor gene inactivation, since most cases associated with a reduced ATM expression show biallelic ATM mutations with no detectable LOH. 23 ATM missense mutations are predominant and have been described across the entire coding region of the gene. Although two independent studies suggested that some of the B-CLL patients are constitutional A-T heterozygotes, 22, 23 Yuille et al 27 showed, by screening 61 individuals in 29 families with B-CLL, that ATM germline mutations do not account for familial clustering of the disease. One investigation has provided evidence that B-CLL patients with reduced ATM protein expression developed a more aggressive form of the disease. 24 Molecular characterizations of 16 ATM mutant B-CLLs demonstrated the absence of somatic hypermutation patterns in the immunoglobulin heavy chain gene, supporting a pregerminal centre origin of the malignant clones. 25 Gene expression in B-CLL was recently explored using microarray analysis. The global gene profile of ATM mutant, TP53 mutant and ATM/TP53 wild-type B-CLLs was similar before ionizing radiations but diverged after DNA damage. These results suggest that the transcriptional response to DNA damage is dependent on ATM function; although ATM and TP53 mutant B-CLLs share a common defect in activation of proapoptotic responses after irradiation, they show differences in activation of prosurvival responses. The severe clinical outcome associated with ATM or TP53 mutant B-CLL tumours may depend on their ability to respond to DNA damage induced by treatments or 'endogenous' stresses (Stankovic et al, Blood First Edition Paper, prepublished online September 4, 2003) .
Mantle cell lymphoma (MCL) is an aggressive lymphoma thought to originate from naïve CD5 þ B cells residing in the follicular mantle zone. Translocation t(11;14)(q13;q32) is considered as the cytogenetic hallmark of this lymphoma, but 11q deletion is also frequently detected. 28 Schaffner et al 29 analysed 12 MCL and found nine cases with biallelic ATM alterations (deletion and mutation or biallelic mutations) in which three were somatic rather than germline. More recently, Camacho et al 30 reported eight ATM gene mutations in 7/20 MCL studied. Three of them were missense mutations localized in the PI-3K domain and five were truncating mutations. Somatic origin was demonstrated in three cases and one truncating mutation was present in the germ line. Deletion of the second allele was found in five of these seven cases; of note, typical MCL with ATM inactivation displayed marked features of chromosomal imbalance when compared to MCL with intact ATM. Molecular profiling of lymphomas screened through microarray-based assays has confirmed that MCL harbour a higher proportion of ATM mutations (43%, 12/28) than other B-cell lymphomas. ATM alterations (eight deleterious mutations and six unclassified missense changes) described in MCL were distributed across the gene. In 2/6 cases, ATM alterations (unclassified missense mutations) were found in the germ line while four were alterations confined to tumour cells. Although based on limited numbers, these studies failed to find a positive correlation between ATM mutation carriers and clinical outcome. 31 ATM alterations with a putative pathogenic effect have been found in 13-20% of diffuse large B-cell lymphomas (DLBCL). 20, 31 Missense mutations were predominant and no clustering effect was apparent. Of note, biallelic inactivation with a second mutation or deletion of the normal allele was found in the majority of the cases. Analysis of the ATM promoter methylation status failed to provide evidence for promoter hypermethylation, indicating that it is a rare event in DLBCL. Of interest, a significant association between ATM mutation and TP53 mutations and/or deletions of the INK4a/ARF locus was observed, suggesting that ATM and the ARF-p53 tumour suppressor pathway may cooperate in the pathogenesis of this lymphoid malignancy. 20 This finding diverges from B-CLL where ATM and TP53 mutations appear to occur in a mutually exclusive pattern. 25, 32 Although only limited number of cases have been yet analysed, available data indicated that ATM gene alterations are rarely detected in peripheral T-cell lymphomas. 20, 31 A recent study performed on Hodgkin's diseases (HD) found multiple ATM germline missense variants, including one homozygous alteration, among 9/64 cases tested suggesting that rare ATM variants may be involved in a subset of HD cases. 33 In addition, diverse studies have investigated the contribution of heterozygous ATM mutation in patients who developed BC following radiation therapy for HD. The data suggest that truncating and missense mutations are not associated with an increased risk of radiation-associated BC after HD.
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Childhood leukaemias and lymphomas
Two initial studies assessing the prevalence of ATM gene alterations have reported contrasting results: one investigation based on a limited number of specimens found 6/19 ATM alterations (31%), most missense mutations, located outside of the PI-3K domain, and present in the germline. These mutations were considered as probable rare polymorphisms because of no evidence for a somatic origin. 36 The second investigation was performed on 18 cases of childhood T-ALL and failed to identify ATM alterations. 37 More recently, Oguchi et al 38 investigated seven childhood acute leukaemia patients (four ALL and three acute myeloid leukaemia) with mixed lineage leukaemia (MLL) gene rearrangement. One child with ALL showed a heterozygous germline missense ATM mutation (P2974L) located in the PI-3K domain. Results of the in vitro and in vivo assays suggest a pathogenic mutation with a possible dominantnegative activity.
In a larger study and by using a more sensitive screening method, we explored 57 sporadic childhood ALL cases (26 B-precursor and 31 T-ALL) for ATM mutations. In all, 25% of these ALL exhibited a genomic ATM alteration. In eight patients (14%), mutations were scored as probably biologically significant. Of interest, the association between these mutations and relapse was found to be statistically significant. Six alterations of potential biological significance were observed in five cases of B-precursor ALL (19%), while five were found in three cases of T-ALL (10%) with similar characteristics as described by Luo et al. In two cases of B-precursor ALL, the ATM alterations were found in the germ line, indicating an ATM carrier status. 39 By using the same approach in childhood lymphomas, our observations suggest that as in adult DLBCL ATM gene alterations are quite prevalent (Pause et al, Blood 2002, 100(11), part 2 of 2, p. 206b, abstract).
Two classes of ATM alterations
Available data indicate that ATM alterations are often detected in lymphoid malignancies and that most are missense mutations. This observation is in contrast with the predominance of truncating mutations observed in A-T-affected families. A model has been proposed by Gatti et al 40 and Meyn 41 to explain this apparent paradox. They considered two different populations of ATM heterozygotes. In the first group, patients carry a truncating allele (including truncating and null mutation) coupled with a normal allele (ATM trun/wt ), a heterozygosity status that is not formally associated with an increased susceptibility to cancer. In the second group, patients present a missense mutation (including nonsilent mutations resulting in amino-acid substitution or short in-frame insertions or deletions) associated with a normal allele (ATM mis/wt ), a heterozygosity status that confers increased susceptibility to cancer. Briefly, ATM trun/wt carriers have a nearly normal phenotype because they produce 50% of a normal form of the protein that is not functionally impaired by the minimal amounts of the truncated protein. In contrast, missense mutations encode for stable but functionally abnormal proteins, which may act as dominant-negative mutants that interfere with the normal protein and therefore lead to a loss of function (Table 1 ). In vitro investigations that have explored the functional relevance of missense mutations support this model. For instance, recombinant ATM containing diverse missense variants observed in sporadic BC patients have been expressed in eukaryotic cells and shown to exert a pathogenic effect by suppressing the kinase activity of the endogenous ATM protein, particularly if they are located in the PI-3K domain. 42 As mentioned above, similar results were described in one case of childhood ALL. 38 Recently, it was shown that unlike atm trun/wt mice carrying a heterozygous null mutation, knock-in mice atm mis/wt carrying a heterozygous missense mutation with a dominant-negative activity (7636del9, an in-frame deletion previously reported in A-T patients) have increased numbers of spontaneous tumors. Leukaemias and lymphomas represented almost one-third of the observed tumours. 43 Only few A-T patients have been reported with homozygous missense mutation (ATM mis/mis ). An A-T family with a homozygote missense ATM mutation (T7271G) was described by Stankovic et al. 5 The A-T patients of this family showed an atypical A-T with an absence of typical telangiectasia, an unusual longevity and an intermediate radiosensibility. Of interest, it was shown that BCs reported in this family segregated with the haplotype carrying the missense mutation (review by Gatti et al 40 ). 
Conclusions
Experimental and clinical evidence support the participation of ATM in the pathogenesis of lymphoid malignancies. Missense mutations prevail over truncating mutations, and their deleterious consequences are increasingly recognized. Further investigations are needed to clarify the contrasting distribution between missense mutations such as those described in sporadic T-PLL, clustered in the catalytic domain of ATM and presumably acquired during tumorigenesis, and those described in B-CLL, MCL and childhood ALL, spanning outside the PI-3K domain and often present in the germ line. As recently explored in B-CLL, gene expression profiling of tumours harbouring different ATM mutations may provide novel clues with regard to the functional repercussions of ATM alterations. The identification of constitutional ATM alterations indicates that the ATM gene may act as 'low-penetrance high-prevalence' cancer susceptibility gene in lymphoid neoplasias as well as in BC. However, if epidemiological, cellular and animal studies have substantiated the missense mutation model, a better delineation of ATM contribution will rest on additional studies to elucidate ATM role(s) in epithelial and lymphoid cell biology.
